A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season

CONCLUSIONS: During the 2018-19 influenza season, influenza-related hospitalization/ER visits and associated costs among people aged ≥ 65 were comparable between aTIV and TIV-HD. aTIV was slightly more effective in preventing influenza-related office visits and any CRD event as compared to TIV-HD in this population.PMID:33810903 | DOI:10.1016/j.vaccine.2021.03.054

Source: Vaccine - April 3, 2021 Category: Allergy & Immunology Authors: Stephen I Pelton Victoria Divino Maarten J Postma Drishti Shah Joaquin Mould-Quevedo Mitch DeKoven Girishanthy Krishnarajah Source Type: research